Latest News

The section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed new evidence-based guidelines for sleep-disordered breathing in hospitalized patients.

Long-term phase 3 extension data showed that pitolisant was generally well tolerated and associated with sustained improvements in excessive daytime sleepiness, sleep inertia, and functional outcomes in adults with idiopathic hypersomnia for more than 2 years.

The phase 3 EMNERGIZE study evaluates whether the complement C2 inhibitor empasiprubart can improve disability and functional outcomes in adults with chronic inflammatory demyelinating polyneuropathy.

Data from phase 3 studies presented at SLEEP 2026 showed that investigational oveporexton was associated with improvements in REM sleep architecture and sleep-related symptoms in patients with NT1.

A preclinical study found that SP16, an LRP1 agonist, reduced mechanical hypersensitivity and cold hyperalgesia in paclitaxel-treated mice in an LRP1-dependent manner, implicating Schwann cell LRP1 as a potential therapeutic target in CIPPN.

A randomized, placebo-controlled study will assess whether weekly subcutaneous imeroprubart can reduce relapse risk in patients with chronic inflammatory demyelinating polyneuropathy despite standard-of-care treatment.

New phase 2 data showed that riliprubart was associated with sustained improvements in patient-reported outcomes at 76 weeks in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

The MAGNAZ trial, the first study evaluating zanubrutinib added to rituximab in anti-MAG polyneuropathy, reported baseline characteristics of 32 enrolled patients at PNS 2026, with efficacy results to follow.

Here's some of what is coming soon to NeurologyLive® this week.

A real-world comparative study found efgartigimod produced similar GBS disability score improvement to plasma exchange at 4 weeks, with significantly greater MRC sum score recovery at weeks 8 and 12, and a comparable safety profile.

Analysis of 1420 patients from the International GBS Outcome Study found no significant difference in GBS disability scores between IVIg and plasma exchange at 4 or 26 weeks after adjusting for key clinical covariates.

An exploratory analysis of the phase 3 ADHERE trial found serum NfL levels correlated with CIDP disease activity and declined with efgartigimod treatment in patients with elevated baseline levels.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ferroptosis!